February 19, 2024Open Access

Inhaled Corticosteroids May Not Affect the Clinical Outcomes of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Although inhaled corticosteroids (ICS) is reportedly associated with a higher risk of pneumonia in chronic obstructive pulmonary disease (COPD), the clinical implications of ICS have not been sufficiently verified to determine their effect on the prognosis of pneumonia.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Chang et al. (Mon,) studied this question.

synapsesocial.com/papers/68e78a5ab6db6435876fc7e0 https://doi.org/https://doi.org/10.4046/trd.2023.0176

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD2014 · 155 citations
2Performance of the CURB-65 Score in Predicting Critical Care Interventions in Patients Admitted With Community-Acquired Pneumonia2018 · 74 citations
3Effect of Fluticasone Propionate on Sputum of Patients With Chronic Bronchitis and Emphysema1996 · 122 citations
4Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease2006 · 315 citations
5Pneumonic vs Nonpneumonic Acute Exacerbations of COPD2002 · 140 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo